# Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

> **NCT06654050** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Mesothelioma
- Malignant Mesothelioma (MM)
- Early-stage Mesothelioma
- Subclinical Mesothelioma
- BRCA1-Associated Protein-1 (BAP1) Mutations
- Early-stage BAP1-associated Malignancies

## Interventions

- **DRUG:** alrizomadlin

## Key facts

- **NCT ID:** NCT06654050
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-03-16
- **Primary completion:** 2026-03-16
- **Final completion:** 2026-03-16
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study is being withdrawn due to the CRADA with the company not being finalized
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06654050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06654050, "Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06654050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*